- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05040685
Axillary Reverse Mapping in Breast Cancer (ARM)
Axillary Reverse Mapping (ARM): Validation of Surgical Tecnique in Breast Cancer Surgery
The axillary mapping reverse (ARM) consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema.
A significant decrease of lymphedema rates in patients who was possible associate ARM technique during the axillary surgery improving the quality of life of these patients. There are different visualisation techniques like fluorescence dye.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Axillary lymph node dissection (ALND) was the standard therapy until 1990-2000, when the technique was replaced, when possible, by another procedure associated with less morbidity: the sentinel lymph node biopsy (SLNB). However, actually, ALND is still the gold standard in some patients. This procedure is associated with substantial morbidity, like lymphedema, shoulder pain, arm numbness, axillary web syndrome and decreased upper-extremity range of motion (ROM), that severely conditions the quality of life of these patients.
In 2007, the investigators had the first reports about a new surgical technique, the axillary mapping reverse (ARM), that consists in differentiating the upper limb lymph nodes from the breast ones in order to preserve them and reduce the possibility of lymphedema.
The current literature shows a significant decrease of lymphedema rates in patients who was possible associate this technique during the axillary surgery improving the quality of life of these patients. There are different visualisation techniques. With the use of indocyanine green, the visualisation rates in the axilla of ARM lymphatics are from 88%, similar to other techniques. Some advantages of fluorescence dye are that no systemic allergic reactions have been reported and the 'green tattoo' disappears quickly.
HYPHOTESIS The axillary mapping reverse (AMR) is able to identify the lymph nodes responsible for lymphatic drainage of the ipsilateral upper limb (ARM nodes) in breast cancer patients who underwent an axillar lymph node dissection.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Hospital de Bellvitge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients who will undergo ALND in the treatment of breast cancer:
- cT4a, cT4c and cT4d.
- cT4b with extensive involvement of the skin.
cN0 with SLNB positive (pN+) that need to associate ALND:
- cT3-T4b.
- >2 lymph node macrometastasis if cTis, cT1 and cT2.
- Patients who underwent mastectomy and it is not possible associate adjuvant radiotherapy.
cN1:
- If primary surgery treatment.
- After neoadjuvant systemic treatment, if there is not a clinical-radiological complete response and/or SLNB positive (ypN+).
cN2:
- If primary surgery treatment.
- After neoadjuvant systemic treatment, if luminal tumours or there is not a clinical-radiological complete response in triple negative or HER2 overexpressed tumours.
- cN3.
Exclusion Criteria:
- Patients with previous axillary surgery (except sentinel node biopsy)
- Patients who did previous axillary radiotherapy treatment.
- Patients who do not wish to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Axillary mapping reverse
Application of axillary mapping reverse technique
|
At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min.
First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes.
And, in a second time, extract ARM nodes for their individualized anatomopathological study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of patients who it is possible preserve ARM nodes
Time Frame: 1 year
|
Determinate the percentage of patients who is possible preserve the ARM node during ALND
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of metastatic ARM
Time Frame: 1 year
|
Determinate the percentage of metastatic ARM nodes.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Carlos Ortega Expósito, MD, Bellvitge Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PR139/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymph Node Cancer Metastatic
-
Istituto Clinico HumanitasActive, not recruitingLymph Node Cancer MetastaticItaly
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingRectal Cancer | Lymph Node Cancer MetastaticItaly
-
Canisius-Wilhelmina HospitalZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingProstate Cancer | Prostate Cancer Metastatic | Lymph Node MetastasesNetherlands
-
Jewish General HospitalQuebec Breast Cancer FoundationRecruitingSentinel Lymph Node | Breast Cancer Female | Lymph Node Metastases | Early-stage Breast Cancer | Axillary MetastasesCanada
-
Novadaq Technologies ULC, now a part of StrykerCompletedBreast Cancer | Sentinel Lymph Node Biopsy | Lymph Node MappingUnited States, Canada
-
University of PennsylvaniaFood and Drug Administration (FDA); EUSA Pharma, Inc.; Castleman Disease Collaborative...RecruitingCastleman Disease | Castleman's Disease | Giant Lymph Node Hyperplasia | Angiofollicular Lymph Hyperplasia | Angiofollicular Lymph Node Hyperplasia | Angiofollicular Lymphoid Hyperplasia | GLNH | Hyperplasia, Giant Lymph Node | Lymph Node Hyperplasia, GiantUnited States
-
Oreste Davide GentiliniIBFM- Consiglio Nazionale delle RicercheRecruitingSentinel Lymph Node | Breast Cancer Female | Node-positive Breast CancerItaly
-
Luzerner KantonsspitalRecruitingLung Cancer | Lymph Node MetastasisSwitzerland
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingCervical Cancer | Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Lymph Node Disease | Lymph Node Metastases | Sentinel Lymph Node Biopsy | Endometrium Tumor | Cervical Neoplasm | Micrometastasis | Cervical TumorItaly
-
Shanghai Chest HospitalUnknown
Clinical Trials on Axillary mapping reverse
-
M.D. Anderson Cancer CenterCompleted
-
University Hospital of FerraraUnknownBreast Cancer LymphedemaItaly
-
University of ArkansasActive, not recruiting
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences CorporationUnknownInvasive Breast Cancer | Ductal Carcinoma in Situ of the BreastCanada
-
Case Comprehensive Cancer CenterNot yet recruitingNode-positive Breast Cancer
-
Zagazig UniversityCompletedEarly Breast Cancer | Arm Lymphedema | Lymphatic Spread of Breast CancerEgypt
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIIUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)TerminatedBreast CancerUnited States
-
University Hospital, LinkoepingRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Breast Carcinoma Metastatic in Lymph Node | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7United States